Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Teva to buy Allergan for $40.5 bln, drops Mylan bid

Teva Pharmaceutical Industries (NYSE:TEVA), an Israeli drugmaker, agreed to buy Dublin-based Allergan PLC's (NYSE:AGN) generic pharmaceuticals business for $40.5 billion in cash and stock, and dropped its hostile offer for Mylan (NASDAQ:MYL). Teva will pay $33.75 billion in cash and $6.75 billion worth of shares at today’s price, or about 10 percent of the enlarged company, the Petach...
Teva to buy Allergan for $40.5 bln, drops Mylan bid
The Allergan acquisition is the latest in an unprecedented wave of healthcare deals since the start of 2014, stretching from large drugmakers buying up smaller rivals, to consolidation among makers of generic medicines, to tie-ups between insurers.

Teva Pharmaceutical Industries (NYSE:TEVA), an Israeli drugmaker, agreed to buy Dublin-based Allergan PLC's (NYSE:AGN) generic pharmaceuticals business for $40.5 billion in cash and stock, and dropped its hostile offer for Mylan (NASDAQ:MYL).

Teva will pay $33.75 billion in cash and $6.75 billion worth of shares at today’s price, or about 10 percent of the enlarged company, the Petach Tikva, Israel-based company said in a statement today. Teva said it plans to review its options with respect to the approximately 4.6 percent of Mylan stock that it owns.

The deal, the largest in Israel's corporate history, bolsters Teva’s position as the world’s largest maker of generic drugs, and gives it greater negotiating power with governments and private-health insurers. 

"Through our acquisition of Allergan Generics, we will establish a strong foundation for long-term, sustainable growth, anchored by leading generics capabilities and a world-class late-stage pipeline that will accelerate our ability to build an exceptional portfolio of products - both in generics and specialty as well as the intersection of the two," Teva’s chief executive officer Erez Vigodman said in the statement.

The deal, which is expected to close in the first quarter of 2016, could give the combined company a market value exceeding that of Lilly, which stood at $94 billion on Friday.

Teva also said Monday that it expected to report better-than-expected sales and earnings for the second quarter ended in June. The company projected earnings excluding certain items of $1.43 a share on revenue of $4.97 billion, down 2 percent from a year ago but up 6 percent excluding the impact from currency changes. Analysts, on average, were expecting earnings of $1.31 a share on sales of $4.92 billion.

For 2015, Teva raised its per-share earnings forecast to a range of $5.15 to $5.40, from its previous range of $5.05 to $5.35. Analysts were expecting per-share earnings of $5.20.

ADRs of Teva jumped 8.5 percent to $67.17 at 9:56 a.m. in New York. Shares of Mylan fell 14 percent to $56.56. Shares of Allergan rose 5.5 percent to $326.02.

The Allergan acquisition is the latest in an unprecedented wave of healthcare deals since the start of 2014, stretching from large drugmakers buying up smaller rivals, to consolidation among makers of generic medicines, to tie-ups between insurers. 

Global healthcare M&A so far this year reached $398.5 billion as of July 23, up 80 percent on a year ago, according to Thomson Reuters data.

The second-largest U.S. health insurer, the Blue Cross-Blue Shield carrier Anthem Inc., is buying rival Cigna for $48 billion in a deal that would make it the nation's biggest insurer by enrollment. Aetna Inc., the nation's third-largest insurer, also plans a $35 billion bid for Humana Inc.

 

View full TEVA profile View Profile

Teva Pharmaceutical Industries Timeline

Related Articles

researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors
woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use